Study #2024-0202
A first-in-human, open-label, multicenter Phase I/II study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1)
MD Anderson Study Status
Enrolling
Treatment Agent
ANV600, ANV600 + pembrolizumab (KEYTRUDA®)
Description
The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor activity of ANV600 administered as a single agent or in combination with pembrolizumab in adult participants with advanced solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor
Study phase:
Physician name:
Apostolia Tsimberidou
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-981-0775
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.